A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

BACKGROUND: To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Patients pre-treated with front-line platinum-free regimens, were randomized to receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallis, Athanasios G, Agelaki, Sophia, Agelidou, Athina, Varthalitis, Ioannis, Syrigos, Kostas, Kentepozidis, Nikolaos, Pavlakou, Georgia, Kotsakis, Athanasios, Kontopodis, Emmanouel, Georgoulias, Vassilis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994826/
https://www.ncbi.nlm.nih.gov/pubmed/21092076
http://dx.doi.org/10.1186/1471-2407-10-633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994826/
https://www.ncbi.nlm.nih.gov/pubmed/21092076
http://dx.doi.org/10.1186/1471-2407-10-633

Ejemplares similares